FY2024 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Analysts at Zacks Research decreased their FY2024 EPS estimates for Bruker in a research note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.40 per share for the year, down from their previous forecast of $2.60. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.75 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.59 EPS, FY2025 earnings at $2.78 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $0.84 EPS, Q3 2026 earnings at $0.82 EPS and FY2026 earnings at $3.42 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.74 earnings per share.

Other analysts have also issued research reports about the stock. Citigroup dropped their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

Bruker stock opened at $57.50 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The firm’s fifty day moving average price is $61.33 and its 200 day moving average price is $64.41. The company has a market capitalization of $8.72 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 3.83 and a beta of 1.20. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.35%. The ex-dividend date is Monday, December 2nd. Bruker’s payout ratio is currently 9.62%.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Several institutional investors have recently modified their holdings of BRKR. Advisors Asset Management Inc. acquired a new stake in Bruker in the 1st quarter valued at about $479,000. Lazard Asset Management LLC grew its position in Bruker by 96.8% in the first quarter. Lazard Asset Management LLC now owns 19,771 shares of the medical research company’s stock worth $1,856,000 after buying an additional 9,724 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Bruker in the first quarter valued at $218,000. Virtu Financial LLC acquired a new stake in shares of Bruker during the 1st quarter valued at $251,000. Finally, Atria Investments Inc bought a new stake in shares of Bruker during the 1st quarter worth $1,142,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.